Development of L-PLA based Intrascleral Implant for Sustained Intraocular Delivery of Dexamethasone Sodium Phosphate
DOI:
https://doi.org/10.3329/sjps.v2i1.5817Keywords:
Dexamethasone Sodium Phosphate, Bioidegradable polymer, Intrascleral implantsAbstract
The present study was carried out to develop biodegradable intrascleral implants of Dexamethasone Sodium Phosphate and to evaluate the release pattern of the drug from the prepared implants. Intrascleral implants were prepared by using biodegradable polymer L-PLA (m.wt. 61,200 Da). Sodium chloride (NaCl), gelatin and glycerol monostearate (GMS) were used in various formulations to observe the effects of these additives on the release of Dexamethasone Sodium Phosphate from the prepared L-PLA based intrascleral implants. Five different formulations were prepared for this study and were coded as FD-1 (10%drug+L-PLA), FD-2 (20%drug+L-PLA), FD-3 (10%drug+L-PLA+5%NaCl), FD-4 (10%drug+L-PLA +5%Gelatin) and FD-5 (10%drug+L-PLA+10% GMS). Discs were prepared and made into appropriate shape before submerging into the buffer solution of pH 7.4 in different vials. The in vitro release profile of Dexamethasone Sodium Phosphate from the implants showed a biphasic release pattern with an initial burst followed by a diffusive phase. It was observed that FD-1 and FD-2 showed 19.63% and 29.87% release on the first day and 24.22% and 38.5% release respectively at day 30. The drug loading of FD-1 and FD-2 was 10% and 20% respectively. Among FD-3, FD-4 and FD-5; FD-3 showed highest release (32.1%) at day 30 in which 5% NaCl was used. FD-4 showed 27.45% release at day 30 where gelatin, a hydrophilic agent was used and FD-5 containing GMS, a lipid material, was found to be most retarding (19.22% at day 30). The results of the dissolution study provide an idea that L-PLA may be successfully used for the preparation of biodegradable intrascleral implant of Dexamethasone Sodium Phosphate.Key words: Dexamethasone Sodium Phosphate; Bioidegradable polymer; Intrascleral implants.
DOI: 10.3329/sjps.v2i1.5817
Stamford Journal of Pharmaceutical Sciences Vol.2(1) 2009: 56-60
Downloads
92
88
Downloads
How to Cite
Issue
Section
License
As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.
